JP5925301B2 - Ｎ−アルキル基を含有するジュウテリウム化化合物の製造方法 - Google Patents

Ｎ−アルキル基を含有するジュウテリウム化化合物の製造方法 Download PDF

Info

Publication number
JP5925301B2
JP5925301B2 JP2014511830A JP2014511830A JP5925301B2 JP 5925301 B2 JP5925301 B2 JP 5925301B2 JP 2014511830 A JP2014511830 A JP 2014511830A JP 2014511830 A JP2014511830 A JP 2014511830A JP 5925301 B2 JP5925301 B2 JP 5925301B2
Authority
JP
Japan
Prior art keywords
alkyl
phenyl
bond
alkylene
deuterated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014511830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014524888A (ja
JP2014524888A5 (enExample
Inventor
イェンス・アッツロート
フォルカー・デルダウ
ヴォルフガング・ホラ
マティーアス・ベラー
ローレンツ・ノイベルト
ディルク・ミヒャリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of JP2014524888A publication Critical patent/JP2014524888A/ja
Publication of JP2014524888A5 publication Critical patent/JP2014524888A5/ja
Application granted granted Critical
Publication of JP5925301B2 publication Critical patent/JP5925301B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/46—Ruthenium, rhodium, osmium or iridium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/07—Monoamines containing one, two or three alkyl groups, each having the same number of carbon atoms in excess of three
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/08—Monoamines containing alkyl groups having a different number of carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014511830A 2011-05-23 2012-05-21 Ｎ−アルキル基を含有するジュウテリウム化化合物の製造方法 Expired - Fee Related JP5925301B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305634.5 2011-05-23
EP11305634 2011-05-23
PCT/EP2012/059344 WO2012160015A1 (en) 2011-05-23 2012-05-21 Process for the preparation of deuterated compounds containing n-alkyl groups

Publications (3)

Publication Number Publication Date
JP2014524888A JP2014524888A (ja) 2014-09-25
JP2014524888A5 JP2014524888A5 (enExample) 2015-07-02
JP5925301B2 true JP5925301B2 (ja) 2016-05-25

Family

ID=46146876

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014511830A Expired - Fee Related JP5925301B2 (ja) 2011-05-23 2012-05-21 Ｎ−アルキル基を含有するジュウテリウム化化合物の製造方法

Country Status (10)

Country Link
US (1) US9340489B2 (enExample)
EP (1) EP2714624B1 (enExample)
JP (1) JP5925301B2 (enExample)
KR (1) KR20140030267A (enExample)
CN (1) CN103702961A (enExample)
CA (1) CA2834920A1 (enExample)
IL (1) IL229037A0 (enExample)
RU (1) RU2013156864A (enExample)
SG (1) SG194625A1 (enExample)
WO (1) WO2012160015A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20170664A1 (es) 2014-06-06 2017-06-10 Res Triangle Inst Agonistas del receptor de apelina(apj) y usos de los mismos
CA2967316C (en) * 2014-11-10 2021-12-14 Forge Life Science, Llc Anti-hcmv compositions and methods
PE20190258A1 (es) 2015-12-09 2019-02-25 Res Triangle Inst Antagonistas del receptor de la apelina (apj) mejorados y usos de los mismos
MX384332B (es) 2016-09-16 2025-03-14 Res Triangle Inst Antagonistas opioides kappa de tetrahidroisoquinolina.
PE20190806A1 (es) 2016-10-12 2019-06-10 Res Triangle Inst Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos
JOP20190072A1 (ar) 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
US10696677B2 (en) 2016-12-21 2020-06-30 Research Triangle Institute Diaryl purine derivatives with improved bioavailability
JP7064507B2 (ja) * 2017-04-27 2022-05-10 デューテリア ビバレッジズ、エルエルシー Ｄ２ｏからの重水素化エタノールの調製方法
EA039766B1 (ru) 2017-04-27 2022-03-11 Дьютерия Бевериджес, Ллс Способ получения дейтерированного этанола из d2
SG11202001684PA (en) 2017-10-06 2020-03-30 Forma Therapeutics Inc Inhibiting ubiquitin specific peptidase 30
CN109748767A (zh) * 2017-11-07 2019-05-14 朱允涛 一种利用微波反应装置制备氘代胺类化合物的方法
ES2988920T3 (es) 2018-05-17 2024-11-22 Forma Therapeutics Inc Compuestos bicíclicos fusionados útiles como inhibidores de la peptidasa 30 específica de ubiquitina
WO2020041344A1 (en) 2018-08-20 2020-02-27 Duke University Methods and compositions for drugs to treat ophthalmic diseases
PL3860989T3 (pl) 2018-10-05 2023-07-10 Forma Therapeutics, Inc. Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30)
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
JP7548906B2 (ja) * 2018-12-21 2024-09-10 テラン バイオサイエンシズ インコーポレイテッド ボリナンセリンの重水素化形態および誘導体
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
CR20230325A (es) 2020-12-30 2023-12-11 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas
JP2024507574A (ja) 2021-02-25 2024-02-20 リサーチ トライアングル インスティテュート アペリン受容体アゴニストとしてのヘテロアリール誘導体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
EP0335918A1 (en) 1987-08-07 1989-10-11 Mallinckrodt Diagnostica (Holland) B.V. Diagnostic or radiotherapeutic composition comprising a hydrogen containing compound
US5075337A (en) * 1989-07-26 1991-12-24 G. D. Searle & Co. Alpha-deuterated 2-alkylaminoacetamide derivatives having reduced toxicity for treatment of CNS disorders
AU652759B2 (en) 1990-06-01 1994-09-08 Aventisub Ii Inc. (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
EP1688412A3 (en) 2001-02-16 2006-08-16 Aventis Pharmaceuticals, Inc. Novel heterocyclic amide derivatives and their use as dopamine D3 receptor ligands
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
TW200413274A (en) * 2002-12-27 2004-08-01 Wako Pure Chem Ind Ltd Deuteration or tritiation method
WO2005070853A1 (ja) * 2004-01-23 2005-08-04 Wako Pure Chemical Industries, Ltd. 混合触媒を用いた重水素化方法
WO2008122010A1 (en) * 2007-04-02 2008-10-09 Concert Pharmaceuticals, Inc. Pharmaceutical calcimimetics
WO2009005069A1 (ja) 2007-07-05 2009-01-08 Wako Pure Chemical Industries, Ltd. ルテニウム触媒を用いた重水素化方法
US20100143287A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. Trifluoromethylphenyl modulators of calcium-sensing receptor

Also Published As

Publication number Publication date
JP2014524888A (ja) 2014-09-25
US9340489B2 (en) 2016-05-17
US20140081019A1 (en) 2014-03-20
IL229037A0 (en) 2013-12-31
WO2012160015A1 (en) 2012-11-29
EP2714624A1 (en) 2014-04-09
EP2714624B1 (en) 2017-12-27
KR20140030267A (ko) 2014-03-11
CN103702961A (zh) 2014-04-02
SG194625A1 (en) 2013-12-30
RU2013156864A (ru) 2015-06-27
CA2834920A1 (en) 2012-11-29

Similar Documents

Publication Publication Date Title
JP2014524888A (ja) Ｎ−アルキル基を含有するジュウテリウム化化合物の製造方法
JP5715127B2 (ja) Ｇｐｒ１１９アゴニスト
Rose et al. Synthesis, configuration, and calcium modulatory properties of enantiomerically pure 5-oxo-1, 4, 5, 6, 7, 8-hexahydroquinoline-3-carboxylates
KR101291575B1 (ko) 페녹시프로필피페리딘류와 -피롤리딘류 및 이들의 히스타민ｈ3-수용체 리간드로의 용도
AU2003292625A1 (en) Selective estrogen receptor modulators
JP2010532359A (ja) テトラヒドロピラノクロメンガンマセレクターゼ阻害剤
JP2015519319A (ja) 新規化合物
FI63229B (fi) Foerfarande foer framstaellning av analgetiskt verkande racemiskt eller diastereomera och optiskt aktiva 2-tetrahydrofurfuryl-5,9beta-dimetyl-6,7-bensomorfaner och deras syraadditionssalter
JP5250627B2 (ja) 新規化合物
FR2639942A1 (fr) Ethers oximes de propenone, procede pour leur preparation et compositions pharmaceutiques les contenant
Roselli et al. Synthesis, antiarrhythmic activity, and toxicological evaluation of mexiletine analogues
RU2418787C2 (ru) 3,5-дизамещенные фенилпиперидины в качестве модуляторов нейротрансмиссии допамина
US20100113792A1 (en) Benzylpiperizine compound
EP2128135A1 (en) Method for synthesis of nitroxyl radical
Pan et al. Dioxane-involving reaction for the synthesis of 3-aryl-1-(2-(vinyloxy) ethoxy) isoquinolines catalyzed by AgOTf
AU2006315684A1 (en) Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
AU2012260964A1 (en) Process for the preparation of deuterated compounds containing N-alkyl groups
US5589500A (en) Substituted 1,1,2-triphenylbutenes and their use in the treatment of cancer
TW201619112A (zh) 4-氧代-2-環己烯酮及6-氧代-2-環己烯酮化合物之組合物及製備方法
Gust et al. Synthesis, Structural Evaluation, and Estrogen Receptor Interaction of 4, 5‐Bis (4‐hydroxyphenyl) imidazoles
Jasper et al. Synthesis of σ receptor ligands with unsymmetrical spiro connection of the piperidine moiety
Li et al. Syntheses of novel tripodal calix [n] cryptands (n= 4, 6) and their extraction abilities toward cations
WO2023096822A1 (en) Substituted 2-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)acetamide analogs as modulators of gspt1 and/or ikzf1 protein
JPS5910661B2 (ja) 新規のｏ−アルキル化オキシムおよびその製造方法
CN107501136A (zh) 一种制备偕二芳基甲胺类化合物的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150512

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160419

R150 Certificate of patent or registration of utility model

Ref document number: 5925301

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees